Subclinical inflammation with increased neutrophil activity in healthy twin siblings reflect environmental influence in the pathogenesis of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1725-1731

  Zhulina, Yaroslava ^a,b   Hahn Strömberg, Victoria ^a,b   Shamikh, Alia ^a,b   Peterson, Christer G B ^c   Gustavsson, Anders ^a,b   Nyhlin, Nils ^a   Wickbom, Anna ^a,b   Bohr, Johan ^a,b   Bodin, Lennart ^d   Tysk, Curt ^a,b   Carlson, Marie ^c   Halfvarson, Jonas ^a,b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

F calprotectin; Genetics; Inflammatory bowel disease; Myeloperoxidase; Nuclear factor kappa B; Subclinical activity; Twins

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE;

ADULT; ARTICLE; ASCENDING COLON; CONTROLLED STUDY; CROHN DISEASE; DIZYGOTIC TWINS; ENTERITIS; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MONOZYGOTIC TWINS; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; RELATIVE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASES IN TWINS; ENVIRONMENTAL EXPOSURE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; NEUTROPHILS; NF-KAPPA B; PEROXIDASE; PROGNOSIS; SIBLINGS; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC; YOUNG ADULT;

EID: 84884574092     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f2d3     Document Type: Article

References (29)

1. Fiocchi C. Inflammatory bowel disease pathogenesis: therapeutic implications. Chin J Dig Dis 2005;6:6-9.
2. Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-5589; discussion 8.
3. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:64-69.
4. Nash S, Stafford J, Madara JL. Effects of polymorphonuclear leukocyte transmigration on the barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1987;80:1104-1113.
5. Parkos CA, Colgan SP, Delp C, et al. Neutrophil migration across a cultured epithelial monolayer elicits a biphasic resistance response representing sequential effects on transcellular and paracellular pathways. J Cell Biol 1992;117:757-764.
6. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-1737.
7. Montalto M, Curigliano V, Santoro L, et al. Fecal calprotectin in firstdegree relatives of patients with ulcerative colitis. Am J Gastroenterol 2007;102:132-136.
8. Bodger K, Halfvarson J, Dodson AR, et al. Altered colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients. Gut 2006;55:973-977.
9. Halfvarson J, Standaert-Vitse A, Järnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 2005; 54:1237-1243.
10. Söderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut 1999;44:96-100.
11. Tysk C, Riedesel H, Lindberg E, et al. Colonic glycoproteins in monozygotic twins with inflammatory bowel disease. Gastroenterology 1991; 100:419-423.
12. Lindberg E, Magnusson KE, Tysk C, et al. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992;33:909-913.
13. Helgeland L, Tysk C, Järnerot G, et al. IgG subclass distribution in serum and rectal mucosa of monozygotic twins with or without inflammatory bowel disease. Gut 1992;33:1358-1364.
14. Lindberg E, Söderholm JD, Olaison G, et al. Intestinal permeability to polyethylene glycols in monozygotic twins with Crohn's disease. Scand J Gastroenterol 1995;30:780-783.
15. Tysk C, Lindberg E, Järnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29: 990-996.
16. Halfvarson J. Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis 2010;17:6-12.
17. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753.
18. Cederlöf R, Friberg L, Jonsson E, et al. Studies on similarity diagnosis in twins with the aid of mailed questionnaires. Acta Genet Stat Med 1961;11:338-362.
19. Lichtenstein P, De Faire U, Floderus B, et al. The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies. J Intern Med 2002;252:184-205.
20. Lampinen M, Rönnblom A, Amin K, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005;54:1714-1720.
21. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997;50:93-105.
22. Peterson CG, Eklund E, Taha Y, et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002;97:1755-1762.
23. Hornung R, Reed L. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg 1990;5:46-51.
24. Bland JM, Altman DG. The use of transformation when comparing two means. BMJ 1996;312:1153.
25. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-54.
26. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-885.
27. Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994;35:68-72.
28. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-1581.
29. Halfvarson J, Jess T, Bodin L, et al. Longitudinal concordance for clinical characteristics in a Swedish-Danish twin population with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1536-1544.